Compare Charles River Laboratories Intl. Inc (CRL) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.79. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF nearer its low. Which is the better fit depends on your goals.
| CRL | FLRN | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $233.60 | $30.86 |
52-Week Low | $145.57 | $30.65 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
FLRN (SPDR Bloomberg Investment Grade Floating Rate ETF) trades at $30.80 with no recent price movement. The technical outlook is bearish with moving averages signaling caution, though RSI levels suggest potential oversold conditions. Recent institutional buying by Farther Finance Advisors and BCS Wealth Management indicates professional interest. The fund focuses on floating-rate investment grade bonds, positioning it as a potential hedge in the current rising rate environment.
FLRN offers exposure to floating-rate debt securities that may outperform in a rising rate environment. The fund's structure provides inflation protection benefits, but faces headwinds from potential credit quality deterioration and market volatility. Current dividend payments of $0.11 per share provide income support, though the bearish technical signals warrant careful monitoring of market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
